Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Earnings for Co-Diagnostics, Inc. (CODX)
Earnings in 2023 (TTM): $-38,110,556
According to Co-Diagnostics, Inc.'s latest financial reports the company's current earnings (TTM) are $-38,110,556. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Co-Diagnostics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-38,110,556 | $-35,332,865 |
| 2022 | $-18,847,234 | $-14,238,249 |
| 2021 | $45.64 M | $36.66 M |
| 2020 | $42.57 M | $42.48 M |
| 2019 | $-6,195,557 | $-6,069,113 |
| 2018 | $-6,271,723 | $-6,271,723 |
| 2017 | $-6,959,232 | $-6,959,232 |
| 2016 | $-1,928,686 | $-1,928,686 |
| 2015 | $-2,043,168 | $-2,043,168 |
| 2014 | $-1,048,124 | $-1,048,124 |